Functional and in silico assessment of MAX variants of unknown significance

Iñaki Comino-Méndez, Luis J. Leandro-García, Guillermo Montoya, Lucía Inglada-Pérez, Aguirre A. de Cubas, María Currás-Freixes, Carolyn Tysoe, Louise Izatt, Rocío Letón, Álvaro Gómez-Graña, Veronika Mancikova, María Apellániz-Ruiz, Massimo Mannelli, Francesca Schiavi, Judith Favier, Anne Paule Gimenez-Roqueplo, Henri J L M Timmers, Giovanna Roncador, Juan F. Garcia, Cristina Rodríguez-AntonaMercedes Robledo, Alberto Cascón

Research output: Contribution to journalArticle

Abstract

Abstract: The presence of germline mutations affecting the MYC-associated protein X (MAX) gene has recently been identified as one of the now 11 major genetic predisposition factors for the development of hereditary pheochromocytoma and/or paraganglioma. Little is known regarding how missense variants of unknown significance (VUS) in MAX affect its pivotal role in the regulation of the MYC/MAX/MXD axis. In the present study, we propose a consensus computational prediction based on five “state-of-the-art” algorithms. We also describe a PC12-based functional assay to assess the effects that 12 MAX VUS may have on MYC’s E-box transcriptional activation. For all but two of these 12 VUS, the functional assay and the consensus computational prediction gave consistent results; we classified seven variants as pathogenic and three as nonpathogenic. The introduction of wild-type MAX cDNA into PC12 cells significantly decreased MYC’s ability to bind to canonical E-boxes, while pathogenic MAX proteins were not able to fully repress MYC activity. Further clinical and molecular evaluation of variant carriers corroborated the results obtained with our functional assessment. In the absence of clear heritability, clinical information, and molecular data, consensus computational predictions and functional models are able to correctly classify VUS affecting MAX. Key messages: A functional assay assesses the effects of MAX VUS over MYC transcriptional activity.A consensus computational prediction and the functional assay show high concordance.Variant carriers’ clinical and molecular data support the functional assessment.

Original languageEnglish
Pages (from-to)1247-1255
Number of pages9
JournalJournal of Molecular Medicine
Volume93
Issue number11
DOIs
Publication statusPublished - Nov 1 2015

Keywords

  • MAX
  • Paraganglioma
  • PC12 cells
  • Pheochromocytoma
  • Variants of unknown significance

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Genetics(clinical)

Fingerprint Dive into the research topics of 'Functional and in silico assessment of MAX variants of unknown significance'. Together they form a unique fingerprint.

  • Cite this

    Comino-Méndez, I., Leandro-García, L. J., Montoya, G., Inglada-Pérez, L., de Cubas, A. A., Currás-Freixes, M., Tysoe, C., Izatt, L., Letón, R., Gómez-Graña, Á., Mancikova, V., Apellániz-Ruiz, M., Mannelli, M., Schiavi, F., Favier, J., Gimenez-Roqueplo, A. P., Timmers, H. J. L. M., Roncador, G., Garcia, J. F., ... Cascón, A. (2015). Functional and in silico assessment of MAX variants of unknown significance. Journal of Molecular Medicine, 93(11), 1247-1255. https://doi.org/10.1007/s00109-015-1306-y